LIVMARLI growth and new FOP launch fund a dense pipeline
- Mirum raised full year 2026 revenue guidance to $715 million to $720 million following strong LIVMARLI demand in adult patients.
- The company won FDA approval for Atebrioz in September 2026 and launched it in October for FOP, making it their fourth commercial medicine.
- Management is targeting five major regulatory submissions in the first half of 2027 across multiple pipeline candidates.
- Research and development spending is expected to drop from roughly 50 percent of revenue to 10 percent by late 2027.
- The company expects operating cash flow to turn positive next year as the commercial footprint scales and research costs normalize.
Scaling commercial assets to fund pipeline bets
Mirum is evolving from a single rare liver story into a broader rare disease franchise. Its core drug, LIVMARLI, treats severe itching tied to rare liver diseases. The bull case is simple. The company needs to keep finding more eligible patients, keep payers covering the drug, and use its commercial footprint to launch newly approved products like Atebrioz.
The commercial execution is strengthening. Management raised full year 2026 revenue guidance to between $715 million and $720 million, fueled by a reliable $10 million to $15 million quarterly step up in adult PFIC uptake for LIVMARLI. The company expanded its U.S. field team to about 60 people to reach more than 4,000 liver health care professionals.
The pipeline offers Mirum several ways to grow, creating an extremely dense catalyst path. Management is preparing for five regulatory submissions in the first half of 2027. These include NDAs for volixibat, a BLA for brelovitug in HDV, and label expansions for both Atebrioz and LIVMARLI. As these trials wrap up, management expects research spending to drop from half of revenue to around 10 percent by late 2027, opening a path to positive operating cash flow.
The bear case centers on execution risks across this busy schedule. Rare disease markets are small, and launches can stall if doctors do not adopt new therapies quickly. The volixibat delay in PSC highlights the ongoing regulatory risks involved in pushing five separate submissions through the FDA in a single half year.
Selling scarce medicines to small markets
Mirum makes money by selling approved medicines for rare diseases. These are not mass market drugs. They are aimed at small patient groups where treatment options are limited and pricing can be high if insurers agree the drug provides value.
The company sells directly in the United States and some European countries. In other places, it uses partners and distributors. Takeda, for example, handles LIVMARLI in Japan under a licensing and supply agreement.
This model can be highly profitable once a medicine is approved. Sales teams can target a clear group of specialists, and a small number of diagnosed patients can still support large revenue. The weak point is that every single patient matters. If diagnosis, reimbursement, safety, or doctor education slips, growth can slow fast.
Mirum also acquires or licenses assets to widen its base. This strategy can speed growth, but it raises the bill for research, milestones, royalties, and commercial buildouts. The Bluejay deal brought brelovitug, while the Incyte agreement brought rights to commercialize zilurgisertib, which is now approved as Atebrioz.
Approved drugs and pipeline options
LIVMARLI
Approved for cholestatic pruritus in Alagille syndrome and PFIC. It is Mirum's largest product, featuring steady quarterly growth in the adult PFIC market.
Atebrioz
Approved in September 2026 for fibrodysplasia ossificans progressiva in patients 12 and older. The U.S. launch commenced in October 2026.
Cholbam and Ctexli
Cholbam treats bile acid synthesis disorders, and Ctexli treats adults with CTX. Mirum groups these as bile acid medicines in its reporting.
Volixibat
Advanced for PSC and PBC. Mirum plans to submit NDAs for this candidate in the first half of 2027 following regulatory negotiations.
Brelovitug
Acquired via Bluejay Therapeutics, this candidate targets chronic hepatitis D virus. A BLA submission is targeted for the first half of 2027.
MRM-3379
An oral CNS-penetrant PDE4D inhibitor for Fragile X syndrome. It expands Mirum beyond liver and bile acid disease into neurocognitive disorders.
One segment, two major sales buckets
Mirum manages the company as one operating segment. For Q1 2026 product sales, LIVMARLI produced $113.804 million and bile acid medicines produced $46.078 million, out of $159.882 million total product sales.
What could break the story
Adult PFIC launch slows
High impact · Medium oddsThe 2026 guidance raise depends heavily on persistent LIVMARLI demand, including an estimated 2,000 adult PFIC patients. Mirum expanded its field team to reach adult liver care settings, but hiring sales representatives does not guarantee prescriptions. If adult hepatologists do not adopt LIVMARLI as expected, the primary growth story weakens.
Reimbursement or pricing pressure
High impact · Medium oddsRare disease drugs depend on high prices and broad insurance coverage. Mirum must keep payers convinced that its approved medicines are worth covering. More denials, larger rebates, or tougher government pricing policies could reduce net sales even if patient demand stays high.
Pipeline execution bottleneck
High impact · Medium oddsA massive portion of future upside sits in the pipeline. Management plans five major regulatory submissions for the first half of 2027. Any manufacturing delays, data questions from the FDA, or simple execution hurdles could delay these timelines and hurt the stock.
Supply and channel concentration
Medium impact · Low oddsMirum relies on a single third-party logistics provider and a single specialty pharmacy for all sales of approved medicines in the United States and Canada. That makes distribution simpler, but it creates a single point of failure. A service disruption could block patient access and hurt reported sales.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Mirum Pharmaceuticals, Inc. in Finn's Biotechnology industry ranking.

